HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol. METHODS: A post hoc analysis of the recently completed Treating to New Targets (TNT) study assessed the predictive value of HDL cholesterol levels in 9770 patients. The primary outcome measure was the time to a first major cardiovascular event, defined as death from coronary heart disease, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. The predictive relationship between HDL cholesterol levels at the third month of treatment with statins and the time to the first major cardiovascular event was assessed in univariate and multivariate analyses and was also assessed for specific LDL cholesterol strata, including subjects with LDL cholesterol levels below 70 mg per deciliter (1.8 mmol per liter). RESULTS: The HDL cholesterol level in patients receiving statins was predictive of major cardiovascular events across the TNT study cohort, both when HDL cholesterol was considered as a continuous variable and when subjects were stratified according to quintiles of HDL cholesterol level. When the analysis was stratified according to LDL cholesterol level in patients receiving statins, the relationship between HDL cholesterol level and major cardiovascular events was of borderline significance (P=0.05). Even among study subjects with LDL cholesterol levels below 70 mg per deciliter, those in the highest quintile of HDL cholesterol level were at less risk for major cardiovascular events than those in the lowest quintile (P=0.03). CONCLUSIONS: In this post hoc analysis, HDL cholesterol levels were predictive of major cardiovascular events in patients treated with statins. This relationship was also observed among patients with LDL cholesterol levels below 70 mg per deciliter. (ClinicalTrials.gov number, NCT00327691 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have shown that HDL cholesterol (HDL-C) levels under statin treatment remain an independent predictor of the risk of cardiovascular events in patients who have been treated with statins to lower LDL-C levels4”
From MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice (2012) · cites this paper as [4]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.151”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [151]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [292]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Self-citationDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- 10.1001/jama.251.3.351 · DOI · Paper page
Cited by
Items 501–600 of 1,001
High-density lipoproteins: Marker of cardiovascular risk and therapeutic target
Toth, P. P., & Davidson, M. H. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.002 · Cited by 28
Brinton, E. A., Kher, U. A., Shah, S., Cannon, C. P., Davidson, M. H., Gotto, A. M., Ashraf, T. B., Sisk, C. M., Dansky, H. M., Mitchel, Y., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.10.005 · Cited by 28
Self-citationGenoux, A., Lichtenstein, L., Ferrières, J., Duparc, T., Bongard, V., Vervueren, P., Combes, G., Taraszkiewicz, D., Elbaz, M., Galinier, M., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0672-9 · Cited by 30
Borja, M. S., Hammerson, B., Tang, C., Savinova, O. V., Shearer, G. C., & Oda, M. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182217 · Cited by 31
Ali, Z., Ma, H., Ayim, I., & Wali, A. (2018) · Journal of Food Biochemistry · doi:10.1111/jfbc.12545 · Cited by 28
Hesse, B., Rovas, A., Buscher, K., Kusche‐Vihrog, K., Brand, M., Marco, G. S. D., Kielstein, J. T., Pavenstädt, H., Linke, W. A., Nofer, J., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.10.017 · Cited by 30
Farag, M. A., Reda, A., Nabil, M., Elimam, D. M., & Zayed, A. (2023) · Food & Function · doi:10.1039/d3fo01949g · Cited by 28
Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?
Hermans, M. P., & Fruchart, J. (2010) · Clinical Lipidology · doi:10.2217/clp.10.65 · Cited by 34
Self-citationGenetics of HDL-C: A Causal Link to Atherosclerosis?
van Capelleveen, J. C., Bochem, A. E., Motazacker, M. M., Hovingh, G. K., & Kastelein, J. J. P. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0326-8 · Cited by 32
Self-citationLiu, J., Wang, W., Wang, M., Sun, J., Liu, J., Li, Y., Qi, Y., Wu, Z., & Zhao, D. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.12.018 · Cited by 29
Karalis, I. K., Bergheanu, S. C., Wolterbeek, R., Dallinga‐Thie, G. M., Hattori, H., van Tol, A., Liem, A. H., & Jukema, J. W. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.509264 · Cited by 28
Zhang, B., Menzin, J. A., Friedman, M., Korn, J. R., & Burge, R. T. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802363198 · Cited by 30
Shatwan, I. M., Winther, K. H., Ellahi, B., Elwood, P. C., Ben‐Shlomo, Y., Givens, I. D., Rayman, M. P., Lovegrove, J. A., & Vimaleswaran, K. S. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0744-2 · Cited by 34
“Elevated triacylglycerol (TAG) and reduced high density lipoprotein cholesterol (HDL-C) concentrations are associated with an increased risk of developing CVD [3 – 5].”
Al‐Rasadi, K., Awan, Z. A., Al-Waili, K., Ruel, I. L., Hafiane, A., Krimbou, L., & Genest, J. J. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.07.010 · Cited by 28
Le-Ha, C., Beilin, L. J., Burrows, S., Huang, R., Oddy, W. H., Hands, B. P., & Mori, T. A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1016 · Cited by 29
Shedding Light on High-Density Lipoprotein Cholesterol
Lavie, C. J., & Milani, R. V. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.08.055 · Cited by 28
Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?
Barter, P. J., & Rye, K. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.004 · Cited by 27
Self-citationLee, H., Choi, J., Kim, Y.-E., Kim, I. H., Kim, B., & Lee, C.-H. (2013) · Preventive Nutrition and Food Science · doi:10.3746/pnf.2013.18.3.157 · Cited by 27
Seo, S. M., Baek, S. H., Jeon, H. K., Kang, S., Kim, D., Kim, W.-S., Kim, H. S., Rha, S., Park, J., Seong, I. W., et al. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.16089 · Cited by 28
Menon, V., Kumar, A., Patel, D. R., John, J. S., Riesmeyer, J., Weerakkody, G. J., Ruotolo, G., Wolski, K., McErlean, E. S., Cremer, P. C., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000943 · Cited by 32
Huang, Y., Liu, X., Lo, K. K.-H., Liu, L., Yu, Y., Chen, C., Huang, J., Feng, Y., & Zhang, B. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s271528 · Cited by 27
Oxidized high‐density lipoprotein enhances inflammatory activity in rat mesangial cells
Zhang, M., Gao, X., Wu, J., Liu, D., Cai, H., Fu, L., & Mei, C. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1102 · Cited by 27
Insull, W., Basile, J., Vo, A. N., Jiang, P. X., Thakkar, R. B., & Padley, R. J. (2009) · Journal of clinical lipidology · doi:10.1016/j.jacl.2009.02.009 · Cited by 27
Nilsson, G., Öhrvik, J., Lönnberg, I., & Hedberg, P. (2009) · Current Gerontology and Geriatrics Research · doi:10.1155/2009/158425 · Cited by 28
Strenuous physical exercise accelerates the lipid peroxide clearing transport by HDL
Välimäki, I. A., Vuorimaa, T., Ahotupa, M., & Vasankari, T. J. (2016) · European Journal of Applied Physiology · doi:10.1007/s00421-016-3422-y · Cited by 26
Ozaki, Y., Tanaka, A., Komukai, K., Ishibashi, K., Tanimoto, T., Kitabata, H., Ino, Y., Kubo, T., Imanishi, T., & Akasaka, T. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-0512 · Cited by 27
Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety
Yadav, R., France, M. W., Younis, N., Hama, S., Ammori, B. J., Kwok, S., & Soran, H. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.690395 · Cited by 27
Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction
Mitsuda, T., Uemura, Y., Ishii, H., Takemoto, K., Uchikawa, T., Koyasu, M., Ishikawa, S., Miura, A., Imai, R., Iwamiya, S., et al. (2016) · Heart and Vessels · doi:10.1007/s00380-016-0823-0 · Cited by 26
Akindele, A. J., Unachukwu, E. G., & Osiagwu, D. D. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.03.044 · Cited by 26
Röhrig, N., Strobl, R., Müller, M., Perz, S., Kääb, S., Martens, E., Peters, A., Linkohr, B., & Grill, E. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.08.012 · Cited by 28
Davidson, M. H. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.071 · Cited by 30
The role of developing breast cancer in alteration of serum lipid profile.
Abdelsalam, K. E. A., Hassan, I. K., & Sadig, I. A. (2012) · Europe PMC (PubMed Central) · Cited by 26
Could high-density lipoprotein cholesterol predict increased cardiovascular risk?
Chang, T. I., Streja, E., & Moradi, H. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000318 · Cited by 29
Nakaya, K., & Ikewaki, K. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000472 · Cited by 29
Park, J. S., Cha, K. S., Lee, H. W., Oh, J., Choi, J. H., Lee, H. C., Hong, T. J., Jeong, M. H., Chae, S. C., & Kim, Y. (2013) · Cardiology Journal · doi:10.5603/cj.a2018.0020 · Cited by 29
CETP‐Inhibition and HDL‐Cholesterol: A Story of CV Risk or CV Benefit, or Both
Nicholls, S. J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1118 · Cited by 25
An evaluation of pitavastatin for the treatment of hypercholesterolemia
Chan, P., Shao, L., Tomlinson, B., Zhang, Y., & Liu, Z.-M. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1544243 · Cited by 28
“HDL-C were predictive of major cardiovascular events and represented a residual risk [88].”
BackgroundHDL Therapy for the Treatment of Cardiovascular Diseases
Parolini, C., Marchesi, M., & Chiesa, G. (2009) · Current Vascular Pharmacology · doi:10.2174/157016109789043856 · Cited by 26
“8 mmol/l) [68].”
Yamazaki, D., Ishida, M., Watanabe, H., Nobori, K., Oguma, Y., Terata, Y., Koyama, T., Iino, K., Kosaka, T., & Ito, H. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-9 · Cited by 27
Uysal, A., Aykutoglu, B., & Ascigil, E. (2020) · Motivation and Emotion · doi:10.1007/s11031-019-09806-5 · Cited by 25
Ferrannini, E., Betteridge, D. J., Dormandy, J., Charbonnel, B. H., Wilcox, R. G., Spanheimer, R. G., Erdmann, E., DeFronzo, R. A., & Laakso, M. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01404.x · Cited by 26
Ji, M. S., Jeong, M. H., Ahn, Y. K., Kim, Y. J., Chae, S. C., Hong, T. J., Seong, I. W., Chae, J. K., Kim, C. J., Cho, M., et al. (2014) · Journal of Cardiology · doi:10.1016/j.jjcc.2014.04.002 · Cited by 29
In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1
Holleboom, A. G., Jakulj, L., Franssen, R., Decaris, J., Vergeer, M., Koetsveld, J., Luchoomun, J., Glass, A., Hellerstein, M. K., Kastelein, J. J. P., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.p028449 · Cited by 26
Self-citationResidual cardiovascular risk among people with diabetes
Dash, S., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13646 · Cited by 27
“heart disease, stroke, peripheral vascular disease and major cardiovascular events.(74) HDL-C facilitates reverse cholesterol transport, a pro-”
BackgroundBergland, A. K., Soennesyn, H., Dalen, I., Rodriguez‐Mateos, A., Berge, R. K., Giil, L. M., Rajendran, L., Siow, R. C. M., Tassotti, M., Larsen, A. I., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00536 · Cited by 25
“This is of clinical interest, as higher HDL-cholesterol is associated with lower cardiovascular risk (Barter et al., 2007), while high levels of total cholesterol, triglycerides and LDL are associated with higher cardiovascular risk (Stone et al.”
Norring-Agerskov, D., Madsen, C. M., Bathum, L., Pedersen, O. B., Lauritzen, J. B., Jørgensen, N. R., & Jørgensen, H. L. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05056-w · Cited by 25
Apolipoprotein A-I primes beta cells to increase glucose stimulated insulin secretion
Nilsson, O., Giudice, R. D., Nagao, M., Grönberg, C., Eliasson, L., & Lagerstedt, J. O. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165613 · Cited by 29
Associations between Serum Levels of Cholesterol and Survival to Age 90 in Postmenopausal Women
Maihofer, A. X., Shadyab, A. H., Wild, R. A., & LaCroix, A. Z. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16306 · Cited by 28
Gao, P., Wen, X., Ou, Q., & Zhang, J. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02760-0 · Cited by 40
Mardi, P., Abdi, F., Ehsani, A., Seif, E., Djalalinia, S., Heshmati, J., Shahrestanaki, E., Gorabi, A. M., & Qorbani, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.957136 · Cited by 32
Kluck, G. E. G., Qian, A. S., Sakarya, E. H., Quach, H., Deng, Y. D., & Trigatti, B. L. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318062 · Cited by 30
Nakamura, Y., Kabayama, M., Godai, K., Tseng, W., Akasaka, H., Yamamoto, K. I., Takami, Y., Takeya, Y., Gondo, Y., Yasumoto, S., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01271-5 · Cited by 31
Sengwayo, D. G., Moraba, M. M., & Motaung, K. S. (2013) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2013-059 · Cited by 25
Costa‐Scharplatz, M., Ramanathan, K., Frial, T., Beamer, B., & Gandhi, S. (2008) · Clinical Therapeutics · doi:10.1016/s0149-2918(08)80061-6 · Cited by 25
Zhou, P., Lu, Z., Gao, P., Wang, P., Cao, Z., Zhang, G., Wang, S., Feng, Y., & Wang, P. (2014) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2014.02.001 · Cited by 31
Mulder, D. J., de Boer, J. F., Graaff, R., de Vries, R., Annema, W., Lefrandt, J. D., Smit, A. J., Tietge, U. J. F., & Dullaart, R. P. F. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.05.011 · Cited by 25
High-density lipoprotein therapeutics and cardiovascular prevention
Fazio, S., & Linton, M. F. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.004 · Cited by 28
Most Promising Therapies in Interventional Cardiology
Kernéis, M., Nafee, T., Yee, M. K., Kazmi, H. A., Datta, S., Zeitouni, M., Afzal, M. K., Jafarizade, M., Walia, S. S., Qamar, I., et al. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1108-x · Cited by 39
Cholesterol Efflux Efficiency of Reconstituted HDL Is Affected by Nanoparticle Lipid Composition
Jebari‐Benslaiman, S., Uribe, K. B., Benito‐Vicente, A., Galicia-García, U., Larrea, A., Alloza, I., Vandenbroeck, K., Ostolaza, H., & Martín, C. (2020) · Biomedicines · doi:10.3390/biomedicines8100373 · Cited by 31
Cordero, A., Bertoméu, V., Mazón, P., Quiles, J., Aznar, J., & Bueno, H. (2009) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2009.00093.x · Cited by 25
6-mo aerobic exercise intervention enhances the lipid peroxide transport function of HDL
Tiainen, S., Luoto, R., Ahotupa, M., Raitanen, J., & Vasankari, T. (2016) · Free Radical Research · doi:10.1080/10715762.2016.1252040 · Cited by 23
The paraoxonase gene family and atherosclerosis
Seo, D., & Goldschmidt‐Clermont, P. J. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0029-3 · Cited by 23
“In another study of patients who already had low or near normal LDL levels, levels of serum HDL were still strongly predictive for coronary heart disease [ 5 ].”
BackgroundManagement of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes
Matikainen, N., & Taskinen, M. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0309-3 · Cited by 27
Ogar, I., Egbung, G. E., Nna, V. U., Atangwho, I. J., & Itam, E. H. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.01.027 · Cited by 24
Josefs, T., Wouters, K., Tietge, U. J. F., Annema, W., Dullaart, R. P. F., Vaisar, T., Arts, I. C. W., Kallen, C., Stehouwer, C. D. A., Schalkwijk, C. G., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.10.012 · Cited by 26
Hu, X., Li, W., Wang, C., Zhang, H., Lu, H., Li, G., Zhou, Y., & Dong, H. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9238566 · Cited by 27
Posadas‐Sánchez, R., Posadas‐Romero, C., Mendoza-Peŕez, E., Caracas-Portilla, N., Cardoso-Saldaña, G. C., Medina-Urrutia, A. X., Galarza, E. J., & Juárez-Rojas, J. G. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.10.017 · Cited by 25
Incremento de las HDL como arma terapéutica en la aterotrombosis
Badimón, J. J., & Ibáñez, B. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70091-9 · Cited by 34
DEEDWANIA, P. C., Singh, V. N., & Davidson, M. H. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.013 · Cited by 26
Evidence for a role of CETP in HDL remodeling and cholesterol efflux: Role of cysteine 13 of CETP
Maugeais, C., Perez, A., von der Mark, E., Magg, C., Pflieger, P., & Niesor, E. J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.07.007 · Cited by 26
Caveats to aggressive lowering of lipids by specific statins
Koh, K. K., Lim, S. K., Sakuma, I., & Quon, M. J. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.09.002 · Cited by 25
High-density lipoprotein levels and risk of cardiovascular events: a review
Mureddu, G. F., Brandimarte, F., & Luca, L. D. (2011) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32834bb3c8 · Cited by 31
Pitavastatin and HDL: Effects on plasma levels and function(s)
Pirillo, A., & Catapano, A. L. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.001 · Cited by 26
Iqbal, A., DAHL, A. R., Lteif, A. N., & Kumar, S. (2017) · Children · doi:10.3390/children4090080 · Cited by 27
Koufakis, T., Karras, S. Ν., Zebekakis, P. E., & Kotsa, K. (2018) · European Journal of Clinical Nutrition · doi:10.1038/s41430-018-0113-2 · Cited by 24
Lavie, C. J., Milani, R. V., & O’Keefe, J. H. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0058 · Cited by 24
Nüsken, K., Petrasch, M., Rauh, M., Stöhr, W., Nüsken, E., Schneider, H., & Dötsch, J. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp178 · Cited by 23
Li, X., Guo, Y., Zhu, C., Xu, R., Qing, P., Wu, N., Jiang, L., Xu, B., Gao, R., & Li, J. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001412 · Cited by 26
Phatak, H. M., Wentworth, C., Sazonov, V., & Burke, T. A. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.03.016 · Cited by 26
Koyama, S., Horie, T., Nishino, T., Baba, O., Sowa, N., Miyasaka, Y., Kuwabara, Y., Nakao, T., Nishiga, M., Nishi, H., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012609 · Cited by 23
Liu, Y., Jia, S., Yuan, D., Xu, N., Jiang, L., Gao, Z., Chen, J., Yang, Y., Gao, R.-L., Xu, B., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-1097 · Cited by 27
Hamooya, B. M., Musonda, P., Mutale, W., Masenga, S. K., Halwiindi, H., Mutengo, K. H., Chiyeñu, K. O. R., Chongwe, G., Koethe, J. R., Lipworth, L. P., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247004 · Cited by 25
“Earlier reports showed that long-term duration of ART is associated with dyslipidemia and CVD complications [33, 34].”
BackgroundInfluentialNicholls, S. J. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.021 · Cited by 23
Jebari‐Benslaiman, S., Uribe, K. B., Benito‐Vicente, A., Galicia-García, U., Larrea, A., Santín, I., Alloza, I., Vandenbroeck, K., Ostolaza, H., & Martín, C. (2022) · Small · doi:10.1002/smll.202105915 · Cited by 29
Shao, Q., Ma, X., Yang, Z., Li, Q.-X., Wang, Y., Liang, J., Shen, H., Liu, X., Zhou, Y., Shi, D., et al. (2022) · PubMed Central · doi:10.11909/j.issn.1671-5411.2022.06.001 · Cited by 29
Kanat, M., Serin, E., Tunçkale, A., Yildiz, O., Şahin, S., Bolayırlı, M., Arinc, H., Dırıcan, A., Karagoz, Y., Altuntaş, Y., et al. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03345757 · Cited by 27
Prospective randomized clinical trial evaluating the impact of vinegar on lipids in non-diabetics
Panetta, C. J., Jonk, Y. C., & Shapiro, A. C. (2013) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2013.32027 · Cited by 25
Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome
Rizzo, M., Longo, R. A., Guastella, E., Rini, G. B., & Carmina, E. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03346706 · Cited by 25
Plasma myeloperoxidase activity and apolipoprotein A-1 expression in chronic hepatitis B patients.
Mohamadkhani, A., Jazii, F. R., Sayehmiri, K., Jafari-Nejad, S., Montaser-Kouhsari, L., Poustchi, H., & Montazeri, G. (2011) · PubMed · Cited by 23
Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
Metzinger, M. P., Saldanha, S., Gulati, J. S., Patel, K. V., El‐Ghazali, A., Deodhar, S., Joshi, P. H., Ayers, C. R., & Rohatgi, A. K. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018136 · Cited by 26
Editorial: [Pleiotropic Effects of Statins: Implications for a Wide Range of Diseases]
Paraskevas, K. I., Stathopoulos, V., & Mikhailidis, D. P. (2008) · Current Vascular Pharmacology · doi:10.2174/157016108785909724 · Cited by 26
The therapeutic potential of CETP inhibitors: a patent review
Wang, X., Li, W., Hao, L., Xie, H., Hao, C., Liu, C., Li, W., Xiong, X., & Zhao, D. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1439476 · Cited by 24
Chami, B., Hossain, F., Hambly, T. W., Cai, X., Aran, R., Fong, G., Vellajo, A., Martin, N., Wang, X., Dennis, J. M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00380 · Cited by 21
“We propose that increases in SAA may predispose to impaired renal function and increased cardiovascular risk, particularly in diseases that involve dyslipidemia and altered/low circulating HDL (73).”
BackgroundInfluentialHigh density lipoprotein in atherosclerosis and coronary heart disease: Where do we stand today?
Zvintzou, E., Karampela, D. S., Vakka, A., Xepapadaki, E., Karavia, E. A., Hatziri, A., Giannopoulou, P. C., & Kypreos, K. E. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106928 · Cited by 27
Anti‐atherogenic effects of high‐density lipoprotein on nitric oxide synthesis in the endothelium
Andrews, K. L., Moore, X. L., & Chin-Dusting, J. P. F. (2010) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2010.05387.x · Cited by 25
Zoungas, S., Curtis, A. J., McNeil, J. J., & Tonkin, A. M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.86 · Cited by 26
Elevated ApoB serum levels strongly predict early cardiovascular events
Gigante, B., Leander, K., Vikström, M., Frumento, P., Carlsson, A. C., Bottai, M., & Fairé, U. D. (2012) · Heart · doi:10.1136/heartjnl-2012-301852 · Cited by 21
Lipoproteínas de alta densidad y reducción de riesgo cardiovascular: ¿promesas o realidades?
Santos‐Gallego, C. G., & Badimón, J. J. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.10.021 · Cited by 24
González‐Juanatey, J. R., Cordero, A., Vitale, G. C., González-Timón, B., Mazón, P., & Bertoméu, V. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.05.022 · Cited by 23
“Triglicéridos (mg/dl) 122 [93-167] 112 [88-149,8] 151 [106,2-188,8] < 0,01”
Pitavastatin – from clinical trials to clinical practice
Masana, L. (2010) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(10)71065-5 · Cited by 24
Metadata
- Authors
- Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C.
- Affiliations
- The Heart Research Institute (AU)
- Cornell University (US)
- SUNY Downstate Health Sciences University (US)
- Pfizer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Alabama (US)
- Institut Pasteur de Lille (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-09-27
- Volume
- 357
- Issue
- 13
- Pages
- 1301-1310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158057499
- Cited by
- 1,610
- References
- 24
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 34 · 2023: 48 · 2022: 36 · 2021: 51 · 2020: 79 · 2019: 72 · 2018: 59 · 2017: 75 · 2016: 90 · 2015: 106 · 2014: 128 · 2013: 126 · 2012: 130
- FWCI
- 113.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HDL cholesterol, LDL cholesterol, very low LDL cholesterol, major cardiovascular events, statin therapy, cardiovascular risk prediction, coronary artery disease, myocardial infarction, stroke, low HDL cholesterol
- MeSH terms
- Atorvastatin, Adult, Aged, Anticholesteremic Agents, Apolipoproteins, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Risk, Multivariate Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.